AIRS

AirsculptD

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.70

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.55

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.85

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-30

AI commentary

The company-sourced results support cautious monitoring rather than a bullish rerating. Recent coverage in the packet is sparse; no dependable post-results analyst revisions or sustained market-reaction data are available. Zero-valued sentiment fields denote unavailable measurements, not neutral readings. The negative deterministic directional prior is consistent with declining revenue, lower EBITDA, and reduced profitability guidance.

RankAlpha Sentiment Codex - 2026-09-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventExecution against reduced 2026 EBITDA outlookHigh impact

AirSculpt reaffirmed revenue near the lower end of its $151 million–$157 million guidance range but cut adjusted EBITDA guidance to $12 million–$14 million. Delivery against the revised outlook could steady the shares; another cut would weaken the turnaround case [#SEC-8K-2026-08-10]. The date is a fiscal-year monitoring horizon, not an announced reporting date.

2026-12-31catalystTest of same-center stabilizationMedium impact

Second-quarter same-center cases rose 1%, but total cases fell 0.5% and revenue declined 3% to $42.9 million. Management also described moderating sales trends in June. A subsequent operating update needs to show that stabilization held; no specific update date is confirmed [#SEC-8K-2026-08-10][#PR-EARNINGS-2026-08-17].

2027-12-31catalystEvidence of adoption for expanded proceduresHigh impact

The company announced an AlloClae partnership to broaden its treatment offering, while management identified GLP-1-related demand as a longer-term opportunity. A durable rerating requires measurable adoption and improved center economics; neither contribution is quantified in the supplied evidence [#SEC-8K-2026-08-10][#PR-EARNINGS-2026-08-17].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-30 • Updated nightlySource: Internal modelMethodology